| name | es-follow-breast-screening-trans-female-no-inc-risk |
| description | Applies standard breast-screening guidelines for transgender females who have been assessed as having no known increased risk of breast cancer. Trigger phrases include transgender female and assessed as no increased breast cancer risk. |
Follow breast-screening guidelines for transgender females with no increased risk
STEP 1 — Gather Information
Collect patient gender identity, current age, duration and type of gender-affirming hormone therapy (estrogen ± anti-androgen), personal and family history of breast cancer, known genetic mutations (e.g., BRCA), prior chest radiation, and any prior breast surgery or mastectomy to determine baseline risk status.
STEP 2 — Rule In / Rule Out
If the patient is a transgender female and has been assessed as having no known increased risk of breast cancer (no personal/family history, no BRCA, no chest radiation, etc.), proceed to step 3; otherwise, follow high‑risk breast‑cancer screening pathways.
STEP 3 — Classify or Stratify
Stratify by age using average‑risk guidelines for cisgender females: ages 40‑49 (consider shared decision‑making for annual mammography), 50‑74 (biennial mammography), 75+ (continue if life expectancy ≥10 years). Adjust for hormone‑therapy‑induced breast density if needed but do not change interval.
STEP 4 — Decide
Recommend screening mammography according to the age‑based interval determined in step 3; if breast tissue is absent (e.g., after total mastectomy), discontinue routine screening and follow post‑mastectomy surveillance.
Clinical Guardrails / Mimics / Pitfalls
Do not withhold screening because of hormone therapy; do not apply male breast‑cancer guidelines; do not delay screening due to concerns about feminization; recognize that estrogen therapy may increase breast density but does not alter recommended screening interval; if a mastectomy has been performed, follow post‑mastectomy guidelines instead of average‑risk screening.
Concrete Clinical Example
A 52‑year‑old transgender female on estradiol 4 mg daily for 3 years reports no personal or family history of breast cancer, no BRCA mutation, and no prior chest radiation; she is assessed as no increased risk. Following step 3, she falls in the 50‑74 age bracket, so step 4 recommends biennial screening mammography.
Source: Endocrine Society Clinical Practice Guideline: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, Wylie C. Hembree et al., 2017, doi:10.1210/jc.2017-01658
